Publications by authors named "R E Burge"
Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis.
J Dermatolog Treat
December 2025
Background: Lebrikizumab monotherapy significantly improved signs and symptoms in patients with moderate-to-severe atopic dermatitis (AD) in phase 3 Advocate1 and ADvocate2 studies.
Objective: To evaluate improvements in patient-reported symptoms and quality-of-life (QoL) measures by Eczema Area and Severity Index (EASI) response categories using pooled Advocate1 and ADvocate2 data (post hoc analysis).
Methods: In the 52-week (W) (16-W induction + 36-W maintenance) double-blind, placebo-controlled ADvocate1 and ADvocate2 studies, patients were randomized (2:1) to receive subcutaneous lebrikizumab 250 mg or placebo every 2 weeks.
Background/objectives: Anterior Gradient-2 (AGR2/PDIA17) is a member of the protein disulfide isomerase (PDI) family of oxidoreductases. AGR2 is up-regulated in several solid tumors, including pancreatic ductal adenocarcinoma (PDAC). Given the dire need for new therapeutic options for PDAC patients, we investigated the expression and function of AGR2 in PDAC and developed a novel series of affinity-matured AGR2-specific single-chain variable fragments (scFvs) and monoclonal antibodies.
View Article and Find Full Text PDFArticle Synopsis
- - Current treatments for autoimmune diseases often fail to achieve long-term remission, prompting interest in therapies that restore balance in the immune system, known as immune resolution; however, there's no clear consensus on how to evaluate these therapies in clinical trials.
- - A systematic literature review (SLR) was conducted using established guidelines to explore expert opinions and previous studies on immune resolution in five autoimmune diseases: asthma, atopic dermatitis, rheumatoid arthritis, systemic lupus erythematosus, and ulcerative colitis; this involved searching databases and conference proceedings from 2013 to 2023.
- - The SLR included 26 publications and found that expert opinions tended to lack specific measures for assessing immune resolution but suggested potential targets and biomarkers for future therapy
Hidradenitis suppurativa (HS) is an inflammatory skin disease associated with high morbidity and disability that has limited treatment options. People from racial and ethnic minority groups may experience greater disease severity and delay to diagnosis. This study assessed the impact of race/ethnicity on HS diagnosis and management in real-world clinical settings.
View Article and Find Full Text PDFArticle Synopsis
- Hidradenitis suppurativa (HS) uniquely affects patients' quality of life (QoL), and current general patient-reported outcome measures (PROMs) may not adequately capture this impact, highlighting the need for a HS-specific PROM.
- The study aimed to validate the Hidradenitis Suppurativa Quality of Life Questionnaire (HiSQOL) by comparing its results with the Dermatology Life Quality Index (DLQI) through a survey involving 677 HS patients across multiple countries.
- Findings showed a strong correlation (0.87) between HiSQOL and DLQI scores, indicating that HiSQOL effectively reflects QoL issues specific to HS, particularly in areas like embarrassment, depression, and anxiety, which were